Abstract
The global pandemic of non-vector borne environmental diseases may, in large part, be attributed to chronic exposures to ever increasing levels of exogenous lipophilic chemicals. These chemicals include persistent organic pollutants, semi-volatile compounds and low molecular weight hydrocarbons. Such chemicals facilitate the sequential absorption of otherwise not absorbed more toxic hydrophilic species that attack numerous body organs and systems, leading to environmental disease. Co-morbidities of non-communicable environmental diseases are alarmingly high, with as many as half of all individuals chronically ill with two or more diseases. Co-morbidity is to be anticipated, since all of the causative chemicals identified have independently been shown to trigger the individual diseases.
Keywords: environmental disease, co-morbidity, diabetes, cardiovascular disease, neurological disease
Introduction
The prevalence of non-vector borne environmental disease in the world has reached pandemic proportions (Murray et al., 2012). In the United States alone, half of all adults have at least one environmental disease and more than a quarter of the adult population suffers from two or more co-morbid environmental diseases (Bauer et al., 2014; Jakovljevic et al., 2013; van Oostrom et al., 2012). Indeed, rapid increases in incidences of environmental diseases have not been limited to the industrialized areas of the globe but have also spread to remote areas including those inhabited by indigenous populations in the tropics and near the poles (Vos et al., 2012). The rapid rise in the prevalence of these diseases can only be linked to environmental effects (Boyle et al., 2010). A common thread in many environmental diseases is the presence of exogenous lipophilic toxic chemicals in the bodies of those affected (Zeliger, 2013; Zeliger, 2013a; Zeliger 2013b).
It has been previously reported that chemically sensitive individuals exposed to low molecular weight hydrocarbons (LMWHCs) had numerous co-morbidities (Zeliger et al. 2012). It can now be reported that exposures to all exogenous lipophilic chemicals cause co-morbidities and that co-morbidity of environmental disease is not limited to just the chemically sensitive people. Exposure to and retention of lipophilic persistent organic pollutants (POPs) semi-volatile and volatile exogenous lipophilic chemicals has been associated with increased prevalence of type 2 diabetes (T2D) (Carpenter, 2008; Lee et al., 2010; Zeliger 2013), cardiovascular disease (Zeliger, 2013a), and neurological disease (Zeliger 2013b). Many other environmental diseases, that affect virtually all body systems, are also associated with exposure to and retention of exogenous lipophilic chemical species. These include: immunological (Marie et al., 2013), musculoskeletal (Al-Bashri et al., 2013; Struijs et al., 2006); and respiratory diseases(Cazzola et al., 2013; Varela et al., 2013; Molen, 2010); as well as numerous cancers (Habib et al., 2013; Sorensen, 2013; van Baal et al., 2010).
A unifying explanation for induction of environmental disease by absorbed exogenous lipophilic chemicals has been previously presented (Zeliger, 2013). Review of the medical and toxicological literature shows that the onset of these diseases is associated with the accumulation of exogenous lipophilic chemicals in body serum, (Gallo et al., 2011; Lee et al., 2011; Lee et al., 2007; Philibert et al., 2009; Cortu et al., 2007). A dose dependent relationship between POPs serum levels and type 2 diabetes (T2D), for example, has been shown to exist (Cortu et al., 2007; Lee et al., 2006). Lipophilic cell membranes are not permeable to most hydrophilic chemicals. Lipophilic chemicals act as solvents and carriers for impermeable hydrophiles to facilitate absorption of species which would not otherwise permeate through the cells’ lipophilic barriers (Zeliger 2003).
It has also been previously shown that mixtures of toxic lipophilic and hydrophilic species produce enhanced toxicities, low-level effects and attacks on organs and/or systems not known to be impacted by either species alone (Zeliger, 2003; Zeliger, 2011). Such effects have been observed following simultaneous exposures to mixtures of lipophililc and hydrophilic chemicals. Environmental disease can be triggered by the initial absorption and retention of lipophilic species followed by the sequential uptake of hydrophilic species that then act together as a toxic mixture, with the absorption of different hydrophiles accounting for the onset of different diseases (Zeliger et al., 2012; Zeliger, 2013; Zeliger, 2013a; Zeliger 2013b).
Though different diseases involve attacks on widely disparate organs and systems, co-morbidity rates are high when individuals are exposed to environmental lipophilic toxins (Zeliger et al., 2012). The onsets of co-morbid diseases do not follow set patterns. Published studies show that individuals with two co-morbid diseases, e.g., T2D and hypertension, are just as likely to become ill with one first as the other first (Sowers et al., 2001), for example. The wide prevalence of co-morbid environmental diseases and the lack of a pattern of onset strongly suggests the common cause for these diseases that has been previously reported on (Zeliger, 2013; Zeliger, 2013a; Zeliger, 2013b).
Methods
The results presented here are based upon a literature review of numerous studies on the toxic effects of the chemicals on the body. These studies include epidemiological and case studies. Adverse effects on health were in all instances diagnosed by appropriate clinical examinations. Data for pairs of co-morbidities were carried out by literature searches for the words, “co-morbidity” and the names of the two diseases, “cardiovascular disease” and “musculoskeletal disease”, for example.
Results
Specific lipophilic chemicals associated with multiple environmental diseases include those previously reported to be associated with T2D, cardiovascular disease and neurological disease. These include non-volatile POPs, semi-volatile and volatile species (Zeliger, 2013; Zeliger, 2013a; Zeliger, 2013b).
Major environmental diseases that have been associated with lipophilic exposure include immunological, neurological, neurodegenerative reproductive, cardiovascular, metabolic, musculoskeletal and carcinogenic ones. These are listed in Table 1.
Table 1.
Major diseases associated with exposures to lipophilic environmental chemicals.
| Type 2 diabetes (T2D): Including metabolic syndrome. |
| Cardiovascular (CVD): Including atherosclerosis, myocardial infarction, hypertension, stroke, coronary heart disease, peripheral heart disease, ischemic heart disease and cardiac autonomic function. |
| Neurological (NRD): Including central nervous system disorders (cognitive, motor and sensory), and peripheral nervous system disorders (neuropathies). |
| Neurodevelopmental (NDV) including autism and attention deficit/hyperactivity disorder (ADHD). |
| Neurodegenerative (NDG) including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). |
| Musculoskeletal (MKS) including osteoarthritis and fibromyalgia (FM). |
| Immunological (IMM) including allergic reaction, autoimmune diseases and chronic fatigue syndrome (CFS). |
| Respiratory (RES) including asthma and chronic obstructive pulmonary disease (COPD). |
| Chemical sensitivity (CMS) including hypersensitivity to inhaled and dermal contact moieties. |
| Obesity (OBS). |
| Cancers (CAN) in multiple organs. |
All of the diseases listed in Table 1 are co-morbid with other environmental diseases that are known to be triggered by exposures to lipophilic chemicals. Figure 1 shows the co-morbidities of the 11 types of these diseases with each other. Table 2 lists co-morbid disease pairs and the references for these. It is of note that of the 55 binary combinations possible, 45 (82%)% have been shown to be co-morbid to date.
Figure 1.
Co-morbidities of chemically induced environmental diseases. References for co-morbidity disease pairs are contained in Table 2. X denotes the existence of co-morbidity between the two diseases.
Table 2.
References for environmental disease co-morbidities.
| Disease Pair | References |
|---|---|
| T2D - CVD | 1995; Colosia et al., 2013; Mannino et al., 2008; Struijs et al., 2006; Sowers et al., 2001; Ramakrishnan et al., 2013. |
| T2D - NRD | Blackman et al., 2013; Sowers et al., 1995; Uzun et al., 2009; Katon, 2008; Struijs et al., 2006; Lee et al., 2008. |
| T2D - NDV | Kohane et al., 2012. |
| T2D - NDG | Bannon, 2002; Duthie et al., 2011; Gage et al., 2003; Struijs et al., 2006. |
| T2D - MSK | Al-Bishri et al., 2013; Mannino et al., 2008; Slater et al., 2011. |
| T2D - IMM | 2009. |
| T2D - RES | van der Molen, 2010; Varela et al., 2013; Cazzola et al., 2013; Mannino et al., 2008; Struijs et al., 2006; Chatila et al., 2008. |
| T2D - CMS | Zeliger et al., 2012. |
| T2D - OBS | Colosia et al., 2013; Sowers et al., 2001; Khaodhiar et al., 1999. |
| T2D - CAN | Habib et al., 2013; van Baal et al., 2011. |
| CVD - NRD | 2008; Uzun et al., 2009; Larsen et al., 2009. |
| CVD - NDV | Tyler et al., 2011. |
| CVD - NDG | Armon, 2004; Bannon, 2011; Duthie et al., 2011; Zamrini et al., 2004; Gage et al., 2003; Perju-Dumbrava et al., 2014. |
| CVD - MSK | Al-Bishri et al., 2013; Slater et al., 2011; Hudon et al., 2008. |
| CVD - IMM | Marrie et al, 2013; Aaron et al., 2000. |
| CVD - RES | Karlstad et al., 2012; van der Molen, 2010; Varela et al., 2013; Chatila et al., 2008. |
| CVD - CMS | Zeliger et al., 2012. |
| CVD - OBS | 2001; Khaodhiar et al., 1999. |
| CVD - CAN | Kreatsoulas et al., 2014; Sorensen, 2013. |
| NRD - NDV | Cristino et al., 2013; Simonoff et al., 2008; Jensen et al., 2014. |
| NRD - NDG | Varela et al., 2013; Gage et al., 2003. |
| NRD - MSK | Marrie et al., 2013; Blackman et al., 2013; McIntyre et al., 2008; Hudon et al., 2008. |
| NRD - IMM | Marrie et al., 2013; Aaron et al., 2001. |
| NRD - RES | Marrie et al., 2013; Karlstad et al., 2012; Blackman et al., 2013; van der Molen, 2010; McIntyre et al., 2008; Cazzola et al., 2013; Chatila et al., 2008. |
| NRD - CMS | Zeliger et al., 2012 |
| NRD - OBS | 2008; Khaodhiar et al., 1999; Luppino et al., 2010. |
| NDV - RES | Fasmer et al., 2011. |
| NDV - OBS | Suren et al., 2014. |
| NDV - CAN | Crespi, 2011. |
| NDG - MSK | 2003. |
| NDG - CAN | Crespi, 2011; Zamrini et al., 2004; Gage et al., 2003 |
| MSK - IMM | 2009; Ciccone et al., 2003. |
| MSK - RES | van der Molen, 2010; Slater et al., 2011; Chatila et al., 2008; Hudon et al., 2008. |
| MSK - CMS | Zeliger et al., 2012 |
| MSK - OBS | 1999; Hudon et al., 2008; |
| MSK - CAN | Sorensen, 2013. |
| IMM - RES | Karlstad et al., 2012; Pinart et al., 2014. |
| IMM - CMS | Zeliger et al., 2012; Ziem et al., 1995; Jason et al., 2000. |
| RES - CMS | Zeliger et al., 2012; Caress et al., 2005. |
| RES - OBS | van der Molen, 2010; Cazzolam et al., 2013; Jung et al., 2014. |
| RES - CAN | Varela et al., 2013; Sorensen, 2013. |
| CMS - OBS | Zeliger et al., 2012. |
| CMA - CAN | Zeliger et al., 2012 |
| OBS - CAN | Khaodhiar et al., 1999. |
Abbreviations: T2D - type 2 diabetes; CVD - cardiovascular disease; NRD - neurological disease; NDV - neurodevelopmental disease; NDG - neurodegenerative disease; MSK - musculoskeletal disease; IMM - immunological disease; RES - respiratory disease; CMS - chemical sensitivity; OBS - obesity; CAN - cancer
Discussion
The environmental diseases reported here are late onset diseases that generally follow decades of living during which physiological breakdown of many systems occur (Wright et al., 2002). All are triggered by a combination of genetic susceptibility and environmental exposure (Zhang et al., 2010). Several mechanisms have been proposed the account for such breakdowns. These include: oxidative stress (Uttara et al., 2009; Bolanos et al., 2009); epigenetic effects (Jakovcevski et al., 2012; Urdinguio et al., 2009; Baccarelli et al., 2009); low intensity inflammation (Miller et al., 2008; Leonhard et al., 2006;); and endocrine disruption (Weiss, 2012; Mostafalou et al., 2013; Colborn et al., 1997). One theory of co-morbidities of environmental diseases is that there are phenotype connections between diseases, i.e., that patients are affected by diseases that are connected to other diseases by a Phenotype Disease Network (Hidalgo et al., 2009; Zhang et al., 2010; Lee et al., 2008). All of these theories are consistent with what is reported here, since exposures to all the lipophilic chemical types described above (POPs, semi-volatile organic compounds, and volatile organic compounds) have been independently been associated with each of the diseases listed in Table 1 (Zeliger, 2013; Zeliger, 2013a; Zeliger, 2013b). It is beyond the scope of this paper to examine these mechanisms in detail. Readers are directed to the references cited for elaboration.
Since all of the diseases listed in Table 1 have been related to exogenous lipophilic adsorption (Zeliger, 2013; Zeliger 2013a; Zeliger 2013b) it is to a great extent predictive that individuals ill with one of these diseases will be co-morbidly ailing with at least one other of these diseases (Zeliger et al., 2012). This can be stated emphatically, as there are numerous studies in the literature showing, that where individuals are co-morbid with two of these diseases, the co-morbidities are independent of the order of onset of the two diseases, i.e., that either of the diseases can precede the other. The following serve as examples of these studies. Somers et al. reported that individuals with autoimmune disease show higher than expected co-morbidities with musculoskeletal disease and type 2 diabetes and that in both instances either of the diseases could precede the other (Somers et al., 2009). In people co-morbid with metabolic syndrome and mental health disorders, either condition can precede the other (Nousen et al., 2013). Obesity and depression are common co-morbid conditions and either one can precede the other (Luppino et al., 2012). Hypertension is about twice as common in diabetics as in those without diabetes and either disease can precede the other (Sowers et al., 1995; Sowers et al., 2001).
Based on the above, it can be stated that one cause of numerous environmental diseases and co-morbidities is chronic lipophilic exposure to lipophiles such as persistent organic pollutants (POPs), semi-volatile exogenous chemicals (SVOCs) and low molecular weight hydrocarbons (LMWHCs). Examples of POPs are polychlorinated biphenyls (PCBs) and organochlorine pesticides (OCs). Examples of semi-volatile compounds are bisphenol A, phthalates and polynuclear aromatic hydrocarbons. Examples of volatile organic compounds are 8 carbon or less aliphatic and single-chain aromatic hydrocarbons. POPs are slowly metabolized and eliminated and are stored in white adipose tissue, from where they are slowly released into the blood stream. SVOCs are more rapidly metabolized and eliminated andLMWHCs are very rapidly metabolized and eliminated, but continued exposure to SVOCs and LMWHCs leads to continuous levels in the blood as well. A steady state of lipophilic load is in effect in the body, and since lipophiles facilitate the absorption of hydrophiles, a body containing high levels of lipophiles is more likely to absorb toxic levels of hydrophiles when exposure to these occurs than one with low levels of lipophiles. This is shown by the dose-response relationships for the onset of T2D, cardiovascular disease and neurological disease (Cortu et al., 2007; Lee et al., 2006; Zeliger, 2013a; Zeliger, 2013b). As a wide variety of exogenous lipophiles have been shown to cause all of the diseases in Table 1, it is total exogenous lipophilic load, regardless of chemical species, that is more predictive of the onset of disease than single chemical considerations.
Further credence to the theory just proposed is provided by the following considerations:
Not only do exogenous lipophiles cause these diseases, but one of these diseases, obesity has also been shown to cause the absorption of lipophiles (See below).
One in four individuals with one of these diseases is likely to be stricken with at lease one more of these diseases (Bauer et al., 2014; Jakovljevic et al., 2013; van Oostrom et al., 2012).
Eleven (11) types of environmental diseases are listed in Table 1. Of the 55 binary combinations of diseases possible, 45 (82%), have been shown to be co-morbid (see Figure 1).
All the diseases in Table 1 are late-onset ones, coming mostly after decades of exposures (Fortin et al., 2005).
A consideration of obesity is in order here. Body Mass Index (BMI) of 30 or greater is considered obese (Luppino et al., 2010). BMI is a predictor of human adipose tissue concentration of POPs (Vaclavik et al., 2006). This is consistent with the fact that obesity is usually associated with CVS, T2D and other diseases, as adipose tissue releases the lipophiles it holds to the blood stream. Obesity is itself caused by POPs, phthalates, bisphenol A and other exogenous lipophiles (Dirinick et al., 2014; Choi et al., 2014; Langer et al., 2014; Lee et al., 2014; Simmons et al., 2014; Lee et al., 2011a). Being obese and having high serum endogenous lipophiles (cholesterol and tryglycerides) contributes to the absorption of these exogenous lipophiles (Wang et al., 2007; Vaclavik et al., 2006). This sets up what is termed here as the Obesity (OBS) – Lipophile (LIP) – Disease (DIS) triangle:
Obesity causes the absorption of toxic lipophiles which in turn cause disease. Toxic lipophiles cause obesity which in turn causes the further absorption of lipophiles which cause disease. Disease causes obesity which causes the absorption of lipohiles which in turn causes further disease. (Dirinick et al., 2014; Choi et al., 2014; Langer et al., 2014; Lee et al., 2014; Simmons et al., 2014).
Finally, it is not implied that lipophilic exposure is the only cause for environmental disease. For example, heavy metals (including arsenic, cadmium, chromium, cobalt, copper, mercury and nickel) are known trigger environmental diseases, including type 2 diabetes, cardovascular diseases and neurological diseases (Carocci et al., 2014; Caciari et al., 2013; Kuo et al., 2013; Baccarelli et al., 2009; Khan, et al., 2014; Agarwal et al., 2011; Mates et al., 2010).
Conclusions
In conclusion, it has been previously shown that chemically sensitive individuals had numerous co-morbidities when exposed to LMWHCs (Zeliger et al., 2012). It can now be stated that exposures to all exogenous lipophiles (POPs and SVOCs, as well as LMWHCs) also produce co-morbidities of environmental diseases in all segments of the population. Exposures to lipophiles result in numerous co-morbid disease pairs affecting widely differing organs and systems. It is theorized that all chronic exposures to lipophilic exogenous chemicals lead to steady states of such compounds in human blood and can cause of a wide range of environmental diseases that affect numerous body organs and systems. Since the lipophiles serve are carriers for the sequential absorption of more toxic hydrophiles, disease onset is dictated not by the individual chemistries of the lipophiles, but by total lipophilic load in the blood. Lipophilic exposure promotes obesity, which promotes the absorption of additional exogenous lipophiles that promote further environmental disease. An obesity-lipophile-disease triangle which promotes the furthering of environmental disease is thus defined.
REFERENCES
- Aaron LA, Burke MM, Buchwald MD. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2012;160:221–227. doi: 10.1001/archinte.160.2.221. [DOI] [PubMed] [Google Scholar]
- Aaron LA, Herrell R, Ashton S, Belcourt M, Schmaling K, Goldberg J, et al. Comorbid clinical conditions in chronic fatigue. J Gen Intern Med. 2001;16:24–31. doi: 10.1111/j.1525-1497.2001.03419.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Agarwal S, Zaman T, Tuzcu EM, Kapadia SR. Heavy metals and cardiovascular disease: results from the National Health and Nutrition Examination Survey (NHANES) 1999–2006. Angiology. 2011;62(5):422–29. doi: 10.1177/0003319710395562. [DOI] [PubMed] [Google Scholar]
- Al-Bishri J, Attar SM, Bassuni N, Al-Yofaiey, Qutbuddeen H, Al-Harthi S, et al. Comorbidity profile among patients with rheumatoid arthritis and the impact on prescription trend. Clin Med Insights: Arthritis and Musculoskeletal Disorders. 2013;6:11–18. doi: 10.4137/CMAMD.S11481. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Antshel KM, Zhang-James Y, Faraone SV. The comorbidity of ADHD and autism spectrum disorder. Expert Rev Neurother. 2013;13(10):1117–28. doi: 10.1586/14737175.2013.840417. [DOI] [PubMed] [Google Scholar]
- Baccarelli A, Bollati V. Epigenetics and environmental chemicals. Curr Opin Pediatr. 2009;21(2):243–51. doi: 10.1097/mop.0b013e32832925cc. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet. 2014;384(9937):45–52. doi: 10.1016/S0140-6736(14)60648-6. [DOI] [PubMed] [Google Scholar]
- Blackman JA, Conaway MR. Developmental, emotional and behavioral co-morbidities across the chronic health condition spectrum. J Pediatr Rehabil Med. 2013;6(2):63–71. doi: 10.3233/PRM-130240. [DOI] [PubMed] [Google Scholar]
- Bolanos JP, Moro MA, Lizasoain I, Almeida A. Adv Drug Deliv Rev. 2009;61(14):1299–1315. doi: 10.1016/j.addr.2009.05.009. [DOI] [PubMed] [Google Scholar]
- Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality and prediabetes prevalence. Popul Health Metr. 2010;8:29–41. doi: 10.1186/1478-7954-8-29. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Caciari T, Sancini A, Fioravanti M, Capozzella A, Casale T, Montuori L, et al. Cadmium and hypertension in exposed workers: a meta-analysis. Int J Occup Med Environ Health. 2013;26(3):440–56. doi: 10.2478/s13382-013-0111-5. [DOI] [PubMed] [Google Scholar]
- Caress SM, Steinemann AC. National prevalence of asthma and chemical hypersensitivity: an examination of potential overlap. JOEM. 2005;47(5):518–22. doi: 10.1097/01.jom.0000161736.54099.44. [DOI] [PubMed] [Google Scholar]
- Carocci A, Rovito N, Sinicropi MS, Genchi G. Mercury toxicity and neurodegenerative effects. Rev Environ Contam Toxicol. 2014;229:1–18. doi: 10.1007/978-3-319-03777-6_1. [DOI] [PubMed] [Google Scholar]
- Carpenter DO. Environmental contaminants as risk factors for developing diabetes. Rev Environ Health. 2008;23(1):59–74. doi: 10.1515/REVEH.2008.23.1.59. [DOI] [PubMed] [Google Scholar]
- Cazzola M, Segreti A, Calzetta L, Rogliani P. Comorbidities of asthma: current knowledge and future research needs. Curr Opin Pulm Med. 2013;19(1):36–41. doi: 10.1097/MCP.0b013e32835b113a. [DOI] [PubMed] [Google Scholar]
- Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549–55. doi: 10.1513/pats.200709-148ET. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Choi J, Eom J, Kim J, Lee S, Kim Y. Association between some endocrine-disrupting chemicals and childhood obesity in biological samples of young girls: a cross-sectional study. Environ Toxicol Pharmacol. 2014;38(1):51–57. doi: 10.1016/j.etap.2014.04.004. [DOI] [PubMed] [Google Scholar]
- Ciccone DS, Natelson BH. Comorbid ilness in women with chronic fatigue syndrome: a test of the single syndrome hypothesis. Psychosomatic Med. 2003;65:268–75. doi: 10.1097/01.psy.0000033125.08272.a9. [DOI] [PubMed] [Google Scholar]
- Colborn T, Dumanoski D, Myers JP. Our stolen future. New York: Penguin Books; 1997. [Google Scholar]
- Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metal Syndr Obes. 2013;6:327–38. doi: 10.2147/DMSO.S51325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cordu N, Schymura MJ, Nogotia S, Rej R, Carpenter DO. Diabetes in relation to serum levels of polychlorinated biphenyls and chlorinated pesticides in adult native Americans. Environ Health Perspect. 2007;115(10):1442–47. doi: 10.1289/ehp.10315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Crespi B. Autism and cancer risk. Autism Research. 2011;4:302–10. doi: 10.1002/aur.208. [DOI] [PubMed] [Google Scholar]
- Cristino AS, Williams SM, Hawi Z, An JY, Bellgrove MA, Schwartz CE, et al. Neurodevelopment and neuropsychiatric disorders represent an interconnected molecular system. Mol Psychiatry. 2013;19(3):294–301. doi: 10.1038/mp.2013.16. [DOI] [PubMed] [Google Scholar]
- Dirinck EL, Dirtu AC, Govidian M, Covaci A, Van Gaal LF, Jorens PG. Exposure to persistent organic pollutants: relationship with abnormal glucose metabolism and visceral adiposity. Diabetes Care. 2014;37(7):1951–58. doi: 10.2337/dc13-2329. [DOI] [PubMed] [Google Scholar]
- Duthie A, Chew D, Soiza RL. Non-psychiatric comorbidity associated with Alzheimer's disease. Q J Med. 2011;104:913–20. doi: 10.1093/qjmed/hcr118. [DOI] [PubMed] [Google Scholar]
- Fasmer OB, Riise T, Eagan TM, Lund A, Dilsaver SC, Hundal O, et al. Comorbidity of asthma with ADHD. J Atten Disord. 2011;15(7):564–71. doi: 10.1177/1087054710372493. [DOI] [PubMed] [Google Scholar]
- Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe MA. Prevalence of multimorbidity among adults seen in family practice. Ann Family Med. 2005;3(3):223–28. doi: 10.1370/afm.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gage H, Hendricks A, Zhang S, Kazis L. The relative health related quality of life of veterans with Parkinson's Disease. J Neurol Neurosurg Psychiatry. 2003;74:163–69. doi: 10.1136/jnnp.74.2.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gallo MV, Schell LM, DeCaprio AP, Jacobs A. Levels of persistent organic pollutant and their predictors among young adults. Chemosphere. 2011;83:1374–82. doi: 10.1016/j.chemosphere.2011.02.071. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Habib SL, Rojna M. Diabetes and risk of cancer. ISRN Oncology. 2013;2013:16. doi: 10.1155/2013/583786. Article ID 583786. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hidalgo CA, Blumm N, Barabasi AL, Christakis NA. A dynamic network approach for the study of human phenotypes. PLoS Computational Biol. 2009;5(4):e1000353. doi: 10.1371/journal.pcbi.1000353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hudon C, Fortin M, Soubhi H. Chronic musculoskeletal conditions and comorbidities in primary care settings. Canadian Family Physician. 2008;54:74–5. [PMC free article] [PubMed] [Google Scholar]
- Jakovcevski M, Akbarian S. Epigenetic mechanisms in neurological disease. Nat Med. 2012;18(8):1194–1204. doi: 10.1038/nm.2828. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jakovljevic M, Ostojic L. Comorbidity and multimorbidity in medicine today: challenges and opportunities for bringing separated branches of medicine closer to each other. Psychiatr Danub. 2013;25(Suppl 1):18–28. [PubMed] [Google Scholar]
- Jason LA, Taylor RR, Kennedy CL. Chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities in a community-based sample of persons with chronic fatigue-like symptoms. Psychosomatic Med. 2000;62:655–63. doi: 10.1097/00006842-200009000-00009. [DOI] [PubMed] [Google Scholar]
- Jensen CM, Steinhausen HC. Cormorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study. Atten Defic Hyperact Discord. 2014 doi: 10.1007/s12402-014-0142-1. June 19, [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
- Jung KH, Perzanowski M, Rundle A, Moors K, Yan B, Chillrud SN, et al. Polycyclic aromatic hydrocarbon exposure, obesity and childhood asthma in an urban cohort. Environ Res. 2014;128:35–41. doi: 10.1016/j.envres.2013.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Karlstad O, Nafstad P, Tverdal A, Skurtveit S, Furu K. Comorbidities in an asthma population 8–29 years old: a study from the Norwegian prescription database. Pharmacoepidemiol. 2012;21(10):1045–52. doi: 10.1002/pds.2233. [DOI] [PubMed] [Google Scholar]
- Katon WJ. The comorbidity of diabetes mellitus and depression. Am J Med. 2008;121(11 Suppl 2):S8–15. doi: 10.1016/j.amjmed.2008.09.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Khan AR, Awan FR. Metals in the pathogenesis of type 2 diabetes. J Diabetes Metabolic Disorders. 2014;13:16. doi: 10.1186/2251-6581-13-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Khaodhiar L, McCowen KC, Blackburn GL. Obesity and its comorbid conditions. Clin Cornerstone. 1999;2(3):17–31. doi: 10.1016/s1098-3597(99)90002-9. [DOI] [PubMed] [Google Scholar]
- Kohane IS, McMurry A, Weber G, McFadden D, Rappaport L, Kunkel L, et al. The co-morbidity burden of children and young adults with autism spectrum disorders. PLoS ONE. 2012;7(4):e33224. doi: 10.1371/journal.pone.0033224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kreatsoulas C, Anand SS, Subramarian SV. An emerging double burden of disease: the prevalence of individuals with cardiovascular disease and cancer. J Intern Med. 2014;275(5):494–505. doi: 10.1111/joim.12165. [DOI] [PubMed] [Google Scholar]
- Kuo CC, Moon K, Thayer KA, Navas-Acien A. Environmental chemicals and type 2 diabetes: an updated systematic review of the epidemiologic evidence. Curr Diab Rep. 2013;13(6):831–49. doi: 10.1007/s11892-013-0432-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Langer P, Ukropec J, Kocan A, Drobna B, Radikova Z, Huckova M, et al. Obesogenic and diabetogenic impact of high organochlorine levels (HCB, p,p-DDE, PCBs) on inhabitants in the highly polluted Eastern Slovakia. Endocr Regul. 2014;48(1):17–24. doi: 10.4149/endo_2014_01_17. [DOI] [PubMed] [Google Scholar]
- Larsen BA, Christenfeld NJS. Cardiovascular disease and psychiatric comorbodity: the potential role of perservative cognition. Cardiovascular Psychiatry Neurology. 2009;2009:8. doi: 10.1155/2d009/791017. Article ID 791017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee DH, Porta M, Jacobs DR, Jr, Vandenberg LN. Chlorinated persistent organic pollutants, obesity, and type 2 diabetes. Endocr Rev. 2014;35(4):557–601. doi: 10.1210/er.2013-1084. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee DH, Lind PM, Jacobs DR, Jr, Salihovic S, van Bavel B, Lind L. Polychlorinated biphenyls and organochlorine pesticides in plasma predict development of type 2 diabetes in the elderly: the prospective investigation of the vasculature in Uppsala seniors (PIVUS) study. Diabetes Care. 2011;34(8):1778–84. doi: 10.2337/dc10-2116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee DH, Steffes MW, Sjoden A, Jones RS, Needham LL, Jacobs DR., Jr Low dose organochlorine pesticides and polychlorinated biphenyls predict obesity, dyslipidemia, and insulin resistance among people free of diabetes. PLoS One. 2011a;26(6):e15977. doi: 10.1371/journal.pone.0015977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee DS, Park J, Kay KA, Christakis NA, Oltavi ZN, Barabasi AL. The implications of human metabolic network topology for disease comorbidity. PNAS. 2008;105(29):9880–85. doi: 10.1073/pnas.0802208105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee DH, Steffes MW, Sjoden A, Jones RS, Needham LL, Jacobs DR., Jr Low dose of some persistent organic pollutants predicts type 2 diabetes: A nested case-control study. Environ Health Perspect. 2010;118(9):1235–42. doi: 10.1289/ehp.0901480. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee DH, Jacobs DR, Jr, Steffes M. Association of organochlorine pesticides with peripheral neuropathy in patients with diabetes or impaired fasting glucose. Diabetes. 2008;57:3108–11. doi: 10.2337/db08-0668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee DH, Lee IK, Porta M, Steffes M, Jacobs DR., Jr Relationship between serum concentrations of persistent organic pollutants and the prevalence of metabolic syndrome among non-diabetic adults: results from the National Health and Nutrition Examination Survey 1999–2002. Diabetologia. 2007;50:1841–51. doi: 10.1007/s00125-007-0755-4. [DOI] [PubMed] [Google Scholar]
- Lee DH, Lee IK, Song K, Steffes M, Toscano W, Baker BA, Jacobs DR., Jr A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes. Diabetes Care. 2006;29(7):1638–44. doi: 10.2337/dc06-0543. [DOI] [PubMed] [Google Scholar]
- Leonhard BE, Myint A. Inflammation and depression: is there a causal conection with dementia? Neurotox Res. 2006;10:149–60. doi: 10.1007/BF03033243. [DOI] [PubMed] [Google Scholar]
- Lugtenberg M, Burgers JS, Clancy C, Westert GP, Schneider EC. Current guidelines have limited applicability to patients with comorbid conditions: a systematic analysis of evidence-based guidelines. PLos ONE. 2011;6(10):e25978. doi: 10.1371/journal.pone.0025987. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers Penninx BWJH, et al. Overweight, obesity, and depression. Arch Gen Psychiatry. 2010;67(3):220–29. doi: 10.1001/archgenpsychiatry.2010.2. [DOI] [PubMed] [Google Scholar]
- Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. European Resp J. 2008;32(4):962–69. doi: 10.1183/09031936.00012408. [DOI] [PubMed] [Google Scholar]
- Marie RA, Hanwell H. General health issues in multiple sclerosis: comorbidities, secondary conditions and health behaviors. Continuum (Minneap Minn) 2013;19(4):1046–57. doi: 10.1212/01.CON.0000433284.07844.6b. [DOI] [PubMed] [Google Scholar]
- Mates JM, Segura JA, Alonso FJ, Marquez J. Roles of dioxins and heavy metals in cancer and neurological diseases using ROS-mediated mechanisms. Free Rad Biol Med. 2010;49(9):1328–41. doi: 10.1016/j.freeradbiomed.2010.07.028. [DOI] [PubMed] [Google Scholar]
- Matson JL, Rieske RD, Williams LW. The relationship between autism spectrum disorders and attention-deficit/hyperactivity disorder: an overview. Res Dev Disabil. 2013;34(9):2475–84. doi: 10.1016/j.ridd.2013.05.021. [DOI] [PubMed] [Google Scholar]
- McIntyre RS, Nguyen HT, Soczynska JK, Lourenco MTC, Woldeyohannes HO, Konarski JZ. Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities. Dialogues Clin Neurosci. 2008;10:203–13. doi: 10.31887/DCNS.2008.10.2/rsmcintyre. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mchanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26:971–82. doi: 10.1200/JCO.2007.10.7805. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mostafalou S, Abdollahi M. Pesticides and human chronic diseases: evidences, mechanisms and perspectives. Toxicol Appl Pharmacol. 2013;268(2):157–77. doi: 10.1016/j.taap.2013.01.025. [DOI] [PubMed] [Google Scholar]
- Murray DJL, Vos T, Lozano R, Naghavi M, Flaxman AD, et al. Disability adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–2223. doi: 10.1016/S0140-6736(12)61689-4. [DOI] [PubMed] [Google Scholar]
- Nousen EK, Franco JG, Sullivan EL. Unraveling the mechanisms responsible for the comorbidity between metabolic syndrome and mental health disorders. Neuroendocrinology. 2013;98(4):254–66. doi: 10.1159/000355632. [DOI] [PMC free article] [PubMed] [Google Scholar]
- O'Dwyer L, Tanner C, van Dongen EV, Greven CU, Bralten J, Zwiers MP, et al. Brain volumetric correlates of autism spectrum disorder symptoms in attention deficit/hyperactivity disorder. PLoS ONE. 2014;9(6):e101130. doi: 10.1371/journal.pone.0101130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Perju-Dumbrava L, Muntean ML, Muresanu DF. Cerebrovascular profile assessment in Parkinson's Disease patients. CNS Neurol Discord Drug Targets. 2014;13(4):712–17. doi: 10.2174/1871527313666140618110409. [DOI] [PubMed] [Google Scholar]
- Philibert A, Schwartz H, Mergler D. An exploratory study of diabetes in First Nation community with respect to the serum concentrations of p,p’-DDE and PCBs and fish consumption. In J Environ Res Public Health. 2009;6(12):3179–89. doi: 10.3390/ijerph6123179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pinart M, Benet M, Annesi-Maesano I, von Berg A, Berdel D, Carlsen KC, et al. Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study. Lancet Respir Med. 2014;2(2):131–40. doi: 10.1016/S2213-2600(13)70277-7. [DOI] [PubMed] [Google Scholar]
- Ramakrishnan J, Majgi SM, Premarajan KC, Lakshminarayanan S, Thangaraj S, Chinnakali P. High prevalence of cardiovascular risk factors among policemen in Puducherry South India. J Cardiovasc Disease Res. 2013;4:112–15. doi: 10.1016/j.jcdr.2013.05.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Simmons AL, Schlezinger JJ, Corkey BE. What are we putting in our food that is making us fat? Food additives, contaminants, and other putative contributors to obesity. Curr Obes Res. 2014;3(2):273–85. doi: 10.1007/s13679-014-0094-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921–29. doi: 10.1097/CHI.0b013e318179964f. [DOI] [PubMed] [Google Scholar]
- Slater M, Perruccio AV, Badley EM. Musculoskeletal comorbidities in cardiovascujlar disease, diabetes and respiratory disease: the impact on activity limitations; a representative population-based study. BMC Public Health. 2011;11:77. doi: 10.1186/1471-2458-11-77. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Somers EC, Thomas SL, Smeeth L, Hall AJ. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? Am J Epidemiol. 2009;169:749–55. doi: 10.1093/aje/kwn408. [DOI] [PubMed] [Google Scholar]
- Sorensen HT. Multimorbidity and cancer outcomes: a need for more research. Clin Epidemiol. 2013;5(Suppl 1):1–2. doi: 10.2147/CLEP.S47149. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. Hypertension. 1995;26:869–79. doi: 10.1161/01.hyp.26.6.869. [DOI] [PubMed] [Google Scholar]
- Sowers JR, Epstein M, Frolich ED. Diabetes, hypertension, and cardiovascular disease an update. Hypertension. 2001;37:1053–59. doi: 10.1161/01.hyp.37.4.1053. [DOI] [PubMed] [Google Scholar]
- Strujis JN, Baan CA, Schellevis FG, Westert GP, van den Bos GAM. Comorbidity in patients with diabetes mellitus: impact on medical health care utilization. BMC Health Serv Res. 2006;6:84–93. doi: 10.1186/1472-6963-6-84. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Suren P, Gunnes N, Roth C, Bresnahan M, Hornig M, Hirtz D, et al. Parental obesity and risk of autism spectrum disorder. Pediatrics. 2014;133(5):1128–38. doi: 10.1542/peds.2013-3664. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tyler CV, Schramm SC, Karafa M, Tang AS, Jain AK. Chronic disease risks in young adults with autism spectrum disorder: forewarned is forearmed. Am J Intell Dev Disabil. 2011;116(5):371–80. doi: 10.1352/1944-7558-116.5.371. [DOI] [PubMed] [Google Scholar]
- Urdinguio RG, Sanchez-Mut JV, Esteller M. Epignetic mechanisms in neurological diseases: genes, syndromes, and therapies. The Lancet Neurology. 2009;8(11):1056–72. doi: 10.1016/S1474-4422(09)70262-5. [DOI] [PubMed] [Google Scholar]
- Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant theropeutic options. Curr Neuropharmacol. 2009;7(1):65–74. doi: 10.2174/157015909787602823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Uzun S, Kozumplik O, Topic R, Jakovljevik M. Depressive disorders and comorbidity: somatic illness vs. side effect. Psychiatria Danub. 2009;21(3):391–98. [PubMed] [Google Scholar]
- Vaclavik E, Tjonneland A, Stripp C, Overvad K, Philippe-Weber J, Raaschou-Nielsen O. Organochlorines in Danish women: predictors of adipose tissue concentrations. Environ Res. 2006;100(3):362–70. doi: 10.1016/j.envres.2005.06.006. [DOI] [PubMed] [Google Scholar]
- Valera MVL, de Oca MM, Halbert R, Muino A, Talamo D, Perez-Padilla R, et al. Comorbidities and health status in individuals with and without COPD in five Latin American cities: the PLATINO study. Arch Bronconeumol. 2013;49(11):468–74. doi: 10.1016/j.arbres.2013.05.003. [DOI] [PubMed] [Google Scholar]
- van Baal PH, Engelfriet PM, Boshuizen HC, van de Kassteele, Schellevis FG, Hoogenveen RT. Co-occurrence of diabetes, myocardial infarction, stroke and cancer: quantifying age patterns in the Dutch population using health survey data. Population Health Metrics. 2011;9:51. doi: 10.1186/1478-7954-9-51/. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van der Molen T. Co-morbidities of COPD in primary care: frequency, relation to COPD, and treatment consequences. Primary Care Resp J. 2010;19(4):326–34. doi: 10.4104/pcrj.2010.00053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Oostrom SH, Picavet HSJ, van Gelder BM, Lemmens LC, Hoeymans N, van Dijk CE, et al. Multimorbidity and comorbidity in te Dutch population – data from general practices. BMC Public Health. 2012;12:715. doi: 10.1186/1471-2458-12-715/. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vos T, Flaxman AD, Naghavi M, Lorenzo R, Michaud C, et al. Years lived with disability(YLDs) for 1160 sequalae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–96. doi: 10.1016/S0140-6736(12)61729-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang RY, Needham LL. Environmental chemicals: from the environment to food, to breast milk, to the infant. J Toxicol Environ Health B Crit Rev. 2007;10(8):597–609. doi: 10.1080/10937400701389891. [DOI] [PubMed] [Google Scholar]
- Weiss B. The intersection of neurotoxicology and endrocrine disruption. Neurotoxicology. 2012;33(6):1410–19. doi: 10.1016/j.neuro.2012.05.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wright A, Charlesworth B, Rudan I, Carothers A, Campbell H. A polygenic basis for late-onset disease. Trends in Genetics. 2003;19(2):97–106. doi: 10.1016/s0168-9525(02)00033-1. [DOI] [PubMed] [Google Scholar]
- Zamrini E, Parrish JA, Parsons D, Harrell LE. Medical comorbidity in black and white patients with Alzheimer's Disease. Southern Med J. 2004;97(1):2–16. doi: 10.1097/01.SMJ.0000077061.01235.42. [DOI] [PubMed] [Google Scholar]
- Zeliger HI, Pan Y, Rea WJ. Predicting co-morbidities in chemically sensitive individuals from exhaled breath analysis. Interdiscp Toxicol. 2012;5(3):123–6. doi: 10.2478/v10102-012-0020-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zeliger HI. Lipophilic chemical exposure as a cause of type 2 diabetes (T2D) Rev Environ Health. 2013;28(1):9–20. doi: 10.1515/reveh-2012-0031. [DOI] [PubMed] [Google Scholar]
- Zeliger HI. Lipophlic chemical exposure as a cause of cardiovascular disease. Interdiscip Toxicol. 2013a;6(2):55–62. doi: 10.2478/intox-2013-0010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zeliger HI. Exposure to lipophilic chemicals as a cause of neurological impairments, neurodevelopmental disorders and neurodegenerative diseases. Interdiscip Toxicol. 2013b;6(3):103–10. doi: 10.2478/intox-2013-0018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zeliger HI. Human toxicology of chemical mixtures. 2nd ed. London: Elsevier; 2012. pp. 40–41. [Google Scholar]
- Zeliger HI. Toxic effects of chemical mixtures. Arch Environ Health. 2003;58(1):23–29. doi: 10.3200/AEOH.58.1.23-29. [DOI] [PubMed] [Google Scholar]
- Zhang Y, De S, Garner JR, Smith K, Wang SA, Becker KG. Systematic analysis, comparison, and integration of disease based human genetic association data and mouse genetic phenotype information. BMC Med Genomics. 2010;3:1. doi: 10.1186/1755-8794-3-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ziem G, Donnay A. Chronic fatigue, fibromyalgia, and chemical sensitivity: overlapping disorders. Arch Int Med. 1995;155(17):1913. [PubMed] [Google Scholar]


